0.05Open0.05Pre Close0 Volume5 Open Interest2.50Strike Price0.00Turnover535.07%IV171.28%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1778Delta0.3684Gamma18.80Leverage Ratio-0.0125Theta0.0000Rho3.34Eff Leverage0.0003Vega
Passage Bio Stock Discussion
• $DBV Technologies(DBVT.US)$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics(ALDX.US)$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova(MNOV.US)$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid(CURV.US)$ +11% (In reaction to earnings/guidance)
• $Novavax(NVAX.US)$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...
- $Consolidated Communications(CNSL.US)$ +14.6%: Searchlight affirms 34.6% active holding; to evaluate the possibility of a further investment in or full acquisition.
- $Voyager Therapeutics(VYGR.US)$ +12.2%: agrees to licensing option with $Novartis AG(NVS.US)$; Voyager receives $54 million upfront.
- $Aegon Ltd(AEG.US)$ +6%: provides update on Russian and Belarusian investments following invasion of Ukraine.
- $AZZ Inc(AZZ.US)$ +...
$TransEnterix Inc(TRXC.US)$
$Clovis Oncology(CLVS.US)$
$3D Systems(DDD.US)$
$Revolve Group(RVLV.US)$
$Passage Bio(PASG.US)$
$TransEnterix Inc(TRXC.US)$
$Clovis Oncology(CLVS.US)$
$3D Systems(DDD.US)$
$Revolve Group(RVLV.US)$
$Passage Bio(PASG.US)$
No comment yet